News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
265,875 Results
Type
Article (14155)
Company Profile (282)
Press Release (251438)
Section
Business (79532)
Career Advice (153)
Deals (13235)
Drug Delivery (35)
Drug Development (50436)
Employer Resources (31)
FDA (5712)
Job Trends (5130)
News (144419)
Policy (10032)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioMidwest Digital (4)
2024 Bio NC Digital (4)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (11)
2024 Biotech Beach Digital (5)
2024 Biotech Beach Standard (3)
2024 Genetown Digital (7)
2024 Genetown Standard (7)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (4)
2024 Pharm Country Standard (4)
2025 BioForest Digital (3)
2025 Lone Star Bio Digital (3)
2026 BioMidwest Elite (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Elite (1)
Academia (909)
Accelerated approval (2)
Adcomms (12)
Allergies (49)
Alliances (21629)
ALS (57)
Alzheimer's disease (813)
Antibody-drug conjugate (ADC) (79)
Approvals (5718)
Artificial intelligence (102)
Autoimmune disease (8)
Automation (5)
Bankruptcy (104)
Best Places to Work (4562)
BIOSECURE Act (5)
Biosimilars (38)
Biotechnology (232)
Bladder cancer (40)
Brain cancer (19)
Breast cancer (135)
Cancer (1189)
Cardiovascular disease (95)
Career advice (132)
Career pathing (2)
CAR-T (102)
Cell therapy (295)
Cervical cancer (5)
Clinical research (40749)
Collaboration (477)
Compensation (206)
Complete response letters (13)
COVID-19 (1031)
CRISPR (35)
C-suite (131)
Cystic fibrosis (75)
Data (1242)
Denatured (11)
Depression (28)
Diabetes (113)
Diagnostics (1286)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (75)
Drug pricing (27)
Drug shortages (3)
Duchenne muscular dystrophy (66)
Earnings (29495)
Editorial (16)
Employer branding (4)
Employer resources (29)
Events (47977)
Executive appointments (384)
FDA (6276)
Featured Employer (32)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (6)
Funding (439)
Gene editing (84)
Generative AI (9)
Gene therapy (219)
GLP-1 (345)
Government (1074)
Grass and pollen (2)
Guidances (18)
Healthcare (6586)
Huntington's disease (21)
IgA nephropathy (19)
Immunology and inflammation (72)
Indications (17)
Infectious disease (1087)
Inflammatory bowel disease (109)
Inflation Reduction Act (8)
Influenza (16)
Intellectual property (52)
Interviews (17)
IPO (7269)
IRA (11)
Job creations (861)
Job search strategy (127)
Kidney cancer (6)
Labor market (4)
Layoffs (198)
Leadership (2)
Legal (1386)
Liver cancer (30)
Lung cancer (169)
Lymphoma (79)
Machine learning (1)
Management (7)
Manufacturing (110)
MASH (46)
Medical device (2588)
Medtech (2589)
Mergers & acquisitions (6232)
Metabolic disorders (344)
Multiple sclerosis (48)
NASH (13)
Neurodegenerative disease (53)
Neuropsychiatric disorders (22)
Neuroscience (1162)
NextGen: Class of 2025 (2014)
Non-profit (853)
Northern California (1453)
Now hiring (21)
Obesity (181)
Opinion (99)
Ovarian cancer (50)
Pain (39)
Pancreatic cancer (49)
Parkinson's disease (99)
Partnered (6)
Patents (101)
Patient recruitment (60)
Peanut (35)
People (25448)
Pharmaceutical (48)
Pharmacy benefit managers (5)
Phase I (14388)
Phase II (18955)
Phase III (11983)
Pipeline (604)
Podcasts (43)
Policy (34)
Postmarket research (852)
Preclinical (6023)
Press Release (30)
Prostate cancer (50)
Psychedelics (35)
Radiopharmaceuticals (211)
Rare diseases (265)
Real estate (1414)
Recruiting (12)
Regulatory (8513)
Reports (14)
Research institute (936)
Resumes & cover letters (17)
Rett syndrome (3)
RNA editing (2)
RSV (10)
Schizophrenia (54)
Series A (85)
Series B (52)
Service/supplier (1)
Sickle cell disease (37)
Southern California (1289)
Special edition (11)
Sponsored (11)
Startups (1971)
State (1)
Stomach cancer (4)
Supply chain (18)
The Weekly (32)
United States (11484)
Vaccines (198)
Venture capitalists (27)
Webinars (7)
Weight loss (101)
Women's health (14)
Worklife (2)
Date
Today (74)
Last 7 days (349)
Last 30 days (1731)
Last 365 days (20199)
2025 (3844)
2024 (20587)
2023 (22436)
2022 (26854)
2021 (27822)
2020 (23397)
2019 (16232)
2018 (11744)
2017 (13751)
2016 (11844)
2015 (14354)
2014 (10399)
2013 (7493)
2012 (7537)
2011 (7616)
2010 (7428)
Location
Africa (148)
Alabama (37)
Alaska (2)
Arizona (50)
Arkansas (5)
Asia (17162)
Australia (2906)
California (3320)
Canada (1018)
China (293)
Colorado (127)
Connecticut (141)
Delaware (84)
Europe (36920)
Florida (386)
Georgia (99)
Idaho (16)
Illinois (200)
India (7)
Indiana (83)
Iowa (1)
Japan (65)
Kansas (58)
Kentucky (5)
Louisiana (3)
Maine (11)
Maryland (430)
Massachusetts (2619)
Michigan (69)
Minnesota (128)
Mississippi (1)
Missouri (22)
Montana (14)
Nebraska (4)
Nevada (14)
New Hampshire (13)
New Jersey (858)
New Mexico (12)
New York (910)
North Carolina (502)
North Dakota (4)
Northern California (1453)
Ohio (102)
Oklahoma (8)
Oregon (21)
Pennsylvania (631)
Puerto Rico (2)
Rhode Island (13)
South America (207)
South Carolina (3)
Southern California (1289)
Tennessee (24)
Texas (372)
Utah (47)
Virginia (66)
Washington D.C. (27)
Washington State (308)
Wisconsin (13)
265,875 Results for "lnc therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pharm Country
New In Vitro Data Showing Matinas BioPharma’s LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024
Matinas BioPharma Holdings, Inc. announces new in vitro data showing the use of LNCs for the delivery of small oligonucleotides was presented yesterday in a poster session at TIDES USA 2024: Oligonucleotide & Peptide Therapeutics, a hybrid in-person and virtual conference underway in Boston.
May 16, 2024
·
5 min read
Pharm Country
Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation
Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) announces positive results from an additional in vivo study in healthy mice with an oral LNC formulation of docetaxel, a well-established chemotherapeutic agent used in the management of multiple metastatic and unresectable tumors.
March 25, 2024
·
8 min read
Pharm Country
Matinas BioPharma’s LNC Platform for the Delivery of Small Oligonucleotides Featured in Two Presentations at the ASGCT Annual Meeting
Matinas BioPharma Holdings, Inc. announces that James J. Ferguson, M.D., Chief Medical Officer of Matinas, will be presenting two abstracts at the ASGCT 27th Annual Meeting being held May 7-11, 2024 in Baltimore highlighting data from ex vivo, in vitro and in vivo studies evaluating the use of Matinas’ LNC platform for the uptake and targeted delivery of small oligonucleotides.
May 7, 2024
·
6 min read
Pharm Country
Matinas BioPharma Announces Positive in vivo Efficacy Results of Oral LNC Docetaxel Formulation in a Melanoma Model
Matinas BioPharma Holdings, Inc. announces positive results from an in vivo animal study of an oral LNC formulation of docetaxel, a well-known chemotherapeutic agent used in the management of multiple metastatic and unresectable tumors.
November 7, 2023
·
6 min read
Pharm Country
Matinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small Oligonucleotides
Matinas BioPharma Holdings, Inc. announces results from a series of in vivo studies demonstrating successful oral delivery of two LNC-formulated small single-strand oligonucleotides that specifically target key inflammatory cytokines TNFα and IL-17A in well-established and validated animal models that mimic acute inflammatory responses seen in human diseases.
December 27, 2023
·
7 min read
Press Releases
HAYA Therapeutics Appoints Former Exscientia Executive Dr. Richard Law as Chief Business Officer
March 13, 2025
·
3 min read
Press Releases
NextRNA Therapeutics Appoints Seasoned Industry Leader Charles Kunsch, Ph.D. to Board of Directors
December 12, 2024
·
3 min read
Business
Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update
Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, reports 2023 financial results and provides a business update.
March 27, 2024
·
15 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Press Releases
NextRNA Therapeutics Expands Executive Team with Appointment of Jesse Smith, PhD as Chief Scientific Officer
September 27, 2024
·
3 min read
1 of 26,588
Next